Modi-1 cancer vaccine for several hard-to-treat cancers
Treatments studied
Part of Cancer, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This Phase 1/2 study tests a cancer vaccine called Modi-1 Moditope in people with advanced triple-negative breast cancer, head and neck cancer, ovarian/high-grade serous cancer, or kidney cancer. It aims to help the immune system better recognize and attack the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have one of these advanced cancers: triple-negative breast, head and neck (SCCHN), high-grade serous ovarian/peritoneal, or renal cell cancer (kidney cancer).
- Your cancer must be advanced and usually not curable with surgery, OR you may be in a head-and-neck surgery timing group.
- You must have measurable tumor spots on a CT or MRI scan (not just symptoms).
- You must be well enough to do study tasks (age 18+ and general health rating ECOG 0 or 1).
- You need certain blood test and organ health levels (for example, bone marrow, kidneys, and liver).
- If you will receive an immune drug (like pembrolizumab, nivolumab, and possibly ipilimumab), you likely must not have had that type of drug before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests NM1F (an anti-PVRIG antibody) in people with advanced solid tumors to see if it’s safe and whether it may work. It also includes pembrolizumab (a PD-1 “checkpoint” medicine), aiming to boost the immune system against the cancer.
This Phase 1 trial tests MEM-288, an oncolytic (cancer-killing) virus, either alone or combined with standard cancer medicines, in people with advanced solid tumors. It’s designed to see how the treatment works and how safe it is in different cancer types and after specific prior therapies.
This trial tests a personalized cancer vaccine designed to train your immune system to fight triple negative breast cancer. It is for people who are already receiving or about to receive the standard KEYNOTE 522 treatment, and the vaccine is given after a few months of that treatment.
This trial tests a combination of an immunotherapy drug (pembrolizumab, also known as Keytruda) with chemotherapy or chemoradiotherapy for people in India with certain advanced cancers of the stomach, bile ducts, or cervix. The goal is to see if adding immunotherapy helps control the cancer better than standard treatment alone.
This trial tests a personalized vaccine made from your tumor's unique markers, combined with the drug pembrolizumab, to help your immune system fight cancer. It is for people with advanced solid tumors who have already tried standard treatments.
This trial tests a personalized vaccine (ODI-2001) that is made from your own tumor. It is given during a break from chemotherapy to see if it is safe and can help keep the cancer from growing.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.